{"transactions":[{"id":3028422,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":146574,"kind":"person","name":"Liatos John","position":1,"cik":"0001821508","reported_name":"Liatos John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Options (Right to Buy)","published_at":"2020-09-18T01:09:44.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":506647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021."}],"balance_after":506647,"derivative":{"exercise_price":1.7,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":506647},"source":{"system":"sec-edgar","filing":"0000905718-20-000973","document":"kintara_fm4sep152020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000090571820000973/kintara_fm4sep152020.xml","form_type":"4"}},{"id":3049891,"issuer":{"id":6601,"kind":"organization","name":"TuHURA Biosciences, Inc./NV"},"owners":[{"id":146574,"kind":"person","name":"Liatos John","position":1,"cik":"0001821508","reported_name":"Liatos John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2020-08-21T20:17:19.000Z","date":"2020-08-19","kind":"purchase","acquired":true,"shares":196750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 125,000 shares of Adgero Biopharmaceuticals Holdings, Inc. (\"Adgero\") common stock, par value $0.0001 per share, in connection with the completion of the merger (the \"Merger\"), on August 19, 2020 (the \"Effective Date\"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share."}],"balance_after":196750,"source":{"system":"sec-edgar","filing":"0001213900-20-023272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498382/000121390020023272/ownership.xml","form_type":"4"}}]}